Morgan Stanley Reiterates Equal Weight Rating on Pfizer Amid Patent Concerns
On April 28, Morgan Stanley maintained its Equal-Weight rating for Pfizer (PFE) with a $28 price target. The firm noted that Pfizer has settled patent disputes with all three Vyndamax generic filers, extending U.S. exclusivity until June 1, 2031. However, the settlement is seen as below investor expectations and raises concerns about the strength of the polymorph patent.
Tickers: $PFE
Topics: dividend stocks investment analysis patents pharmaceuticals